Greenland Mines Ltd (GRML)
Nasdaq · Basic Materials · Other Precious Metals & Mining
$7.34−6.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $98.0M
- 52-week range
- $2.82 – $37.00
- 52-week change
- −73.47%
- EPS (trailing)
- −$9.74
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Net income
- −$10.6M
- Diluted EPS
- −$0.22
From the company’s annual report on SEC EDGAR.
About Greenland Mines Ltd
Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland and the Sarartoq neodymium-praseodymium (Nd-Pr) rare earths project in Southwest Greenland. The company is also involved in the development of KLTO-202, a gene therapy for the treatment and prevention of amyotrophic lateral sclerosis; and KLTO-101 for the treatment or prevention of Alzheimer's disease, as well as therapies to treat Parkinson's and other age-related disorders. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.
Headquarters: Charlotte, United States · 5 employees · greenlandmines.com